Compounds and methods for the targeted degradation of bromodomain-containing proteins
US-2017065719-A1 · Mar 9, 2017 · US
Dihydrobenzimidazolones for medical treatment
US11254672B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11254672-B2 |
| Application number | US-202016809325-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 4, 2020 |
| Priority date | Sep 4, 2017 |
| Publication date | Feb 22, 2022 |
| Grant date | Feb 22, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
First claim
Opening claim text (preview).
We claim: 1. A compound selected from or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 of the formula or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 of the formula or a pharmaceutically acceptable salt thereof. 4. The compound of claim 1 of the formula or a pharmaceutically acceptable salt thereof. 5. The compound of claim 1 of the formula or a pharmaceutically acceptable salt thereof. 6. The compound of claim 1 of the formula or a pharmaceutically acceptable salt thereof. 7. The compound of claim 1 of the formula or a pharmaceutically acceptable salt thereof. 8. The compound of claim 1 of the formula or a pharmaceutically acceptable salt thereof. 9. A compound selected from or a pharmaceutically acceptable salt thereof. 10. The compound of claim 9 of the formula or a pharmaceutically acceptable salt thereof. 11. The compound of claim 9 of the formula or a pharmaceutically acceptable salt thereof. 12. The compound of claim 9 of the formula or a pharmaceutically acceptable salt thereof. 13. The compound of claim 9 of the formula or a pharmaceutically acceptable salt thereof. 14. A compound selected from or a pharmaceutically acceptable salt thereof. 15. The compound of claim 14 of the formula or a pharmaceutically acceptable salt thereof. 16. The compound of claim 14 of the formula or a pharmaceutically acceptable salt thereof. 17. The compound of claim 14 of the formula or a pharmaceutically acceptable salt thereof. 18. The compound of claim 14 of the formula or a pharmaceutically acceptable salt thereof. 19. The compound of claim 14 of the formula or a pharmaceutically acceptable salt thereof. 20. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of claim 1 optionally in a pharmaceutically acceptable carrier. 21. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of claim 9 optionally in a pharmaceutically acceptable carrier. 22. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of claim 14 optionally in a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Bridged systems · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11254672B2 cover?
- The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
- Who is the assignee on this patent?
- C4 Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D235/26. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).